Tiziana Life Sciences Ltd (NASDAQ:TLSA)
| Market Cap | $79.45M-64.1% |
| Revenue (ttm) | $0 |
| Net Income | -$25.19M-14.4% |
| EPS | -$0.21+0.5% |
| Shares Out | 128.03M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 231,243 |
| Open | $0.68 |
| Previous Close | $0.68 |
| Day's Range | $0.61 - $0.68 |
| 52-Week Range | $0.55 - $1.90 |
| Beta | 0.46 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | n/a |
About TLSA
Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
1 firm rating TLSA in the last 3 months, one vote each. Issuer-paid research is not counted.
$TLSA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in TLSA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TLSA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TLSA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New TLSA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TLSA from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from TLSA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Positive clinical trial results and mechanism of action data for lead MS program support advancement toward partnerships and commercialization.
